RT @sammiches14: Amazing turnout at @SCAI from the @BWHIntCard crew this year! So happy to be a part of this team @RaghavG_MD @ZaidAlMarzoo….

RT @SCAI: 🎊 Big congratulations to @sammiches14, recipient of the 2025–26 #SCAIWIN CHIP Fellowship! This prestigious award supports the adv….

Join millions who have switched to Grok.

RT @RaghavG_MD: #SCAI2025 @Ajar_Kochar We presented our very own ERGO CATH study. In this pilot study we QUANTIFY the magnitude of ergonomi….

RT @Ajar_Kochar: Really proud of @RaghavG_MD Greta Campbell, @PrakritiGaba @ZaidAlMarzooq and others who helped complete ERGO CATH a prospe….

RT @Ajar_Kochar: Looking forward to the #SCAI First Interventional Fellow Edu prgm on Wed Feb 19 630pm, Del Frisco's (250 Northern Ave, Bos….

RT @Ajar_Kochar: Gr8 Grand Rounds @BrighamResearch talk by Dr Blankenberg on among other things AI support tools for rapid MI diagnosis. @P….

RT @MyJSCAI: 🗣️Are There Disparities in the Utilization of the #Impella Device in Acute Myocardial Infarction & #CS in the US?🔎. Watch the….

RT @MyJSCAI: 🔖Post-FDA clearance, Impella use is on the rise. 🔎The authors evaluated Impella use in #AMICS & found no race/SES disparities….

RT @SmithBIDMC: The Smith Center will be at #ACC24! Full line-up in the thread below. Register here to make sure you catch all the present….

RT @AHAScience: 🆕 The 2024 Statistical Update is available now! . Heart disease remains the leading cause of death in U.S., yet fewer than….

RT @SunnyVMD: 1/ Wonderful to present our #TVTRegistry analysis on HF #GDMT prior to mitral TEER at the #ESCCongress Young Investigator Awa….

RT @BidmcCvi: Can Impella effectiveness compared with alternative Tx for AMICS be evaluated in an observational claims dbase? @SmithBIDMC &….

@Ajar_Kochar @EricSecemskyMD @enricoferroMD @CAUSALab .#MCS #AMICS #CardiogenicShock #CriticalCareCardiology.

Want to learn more about how to interpret these findings in light of current challenges with using observational studies and how we can move forward? . Check out the editorial by @djc795 & @manesh_patelMDfor their take and some key lessons. 10/10.

We conclude that commonly used observational data sets cannot support a causal interpretation of the estimates produced by different analyses used for the evaluation of Impella in AMICS. RCTs of MCS will allow valid comparisons and help resolve ongoing controversies. 9/10.

In the instrumented difference-in-differences analysis, .🚫 the 95% CIs were too wide to make any meaningful conclusion about harm/benefit. 8/10

In the instrumental variable analysis (method 3), Impella was also a/w ⬆️ in 30-day mortality (albeit w/ a wider 95%CI). 🚫 Assumption Violation -no exchangeability (i.e., patient & institutional differences in baseline characteristics across levels of the instrument). 7/10

In the IPTW & Grace period analyses (methods 1 & 2), Impella appeared to be a/w ⬆️ in 30-day mortality. 🚫 Assumption Violation - unmeasured confounding, as patients receiving Impella had ⬆️ frequency of factors a/w severe illness (e.g. intubation, RHC, vasopressor use). 6/10

Overall, while some methods showed an a/w worse outcomes and others were too imprecise to draw conclusions, there were important assumption violations for each of the methods that limit our causal interpretability of these results. Key findings to follow (see figure). 5/10

We included 23,478 patients with AMICS undergoing PCI between 10/2015 and 12/2019. 🔴 4,063 received Impella. 🔴 12,451 received intra-aortic balloon pump (IABP). 🔴 6,694 received medical therapy. 4/10